Divamics
Latest round
- Series A
Last raised
- May 2025
Total raised
- Undisclosed
Investors
- 2
About Divamics
Established in 2021 and based in Suzhou, China, Divamics operates as a biopharmaceutical company that focuses on providing AI pharmaceutical services. Zheng Zheng, the company's founder and CEO, has a PhD in Chemistry from the University of Florida. The company focuses on new drug research and development. The main products are computational chemistry services and new drug research and development pipeline projects based on artificial intelligence drug research and development platforms. Computational chemistry services include target drugability analysis, high-flexibility target modeling, and macromolecular and small molecule drug structure screening. The new drug research and development pipeline includes IMC001, IMC002, IMC008, etc. Among them, IMC001 is indicated for EpCAM-positive advanced gastric cancer and esophagogastric junction adenocarcinoma. The company generates revenue by providing computational chemistry services and new drug research and development services.
Who invested in Divamics
2 investors across 2 rounds
See all investors in Divamics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Divamics
Who invested in Divamics?
Divamics has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Divamics raised?
Divamics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Divamics last raise money?
Divamics's most recent round on record is a Series A, in May 2025.
What does Divamics do?
Established in 2021 and based in Suzhou, China, Divamics operates as a biopharmaceutical company that focuses on providing AI pharmaceutical services.
Where is Divamics headquartered?
Divamics is headquartered in Suzhou, China.
Which VCs invest in companies like Divamics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Divamics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Divamics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.